10-Q: Integer Holdings Reports Strong Sales, Strategic Acquisitions

Integer Holdings Corporation announced increased sales and gross profit for Q3 and YTD 2025, driven by strategic acquisitions and demand, despite a significant one-time debt conversion expense impacting year-to-date net income.

Summary

• Sales for Q3 2025 increased by 8.4% to $467.691 million, and YTD 2025 sales rose by 9.0% to $1,381.577 million, compared to the same periods in 2024.
• Gross profit for Q3 2025 grew by 8.2% to $126.160 million, and YTD 2025 gross profit increased by 9.8% to $375.630 million.
• Diluted earnings per share from continuing operations for Q3 2025 increased to $1.11 from $0.99 in Q3 2024.
• Year-to-date diluted earnings per share from continuing operations decreased to $1.52 from $2.49, primarily due to a $46.7 million debt conversion inducement expense recognized in Q1 2025.
• Acquired Precision Coating LLC for $153.5 million and VSi Parylene for $24.0 million in early 2025, contributing $42.1 million to year-to-date Cardio & Vascular sales.
• Issued $1.0 billion in 1.875% Convertible Senior Notes due 2030 and used proceeds to exchange $383.7 million of 2028 Convertible Notes and pay down existing credit facilities.
• Reduced floating-rate debt to $101 million from $501 million at December 31, 2024, with approximately 92% of principal debt now fixed rate.
• The Portable Medical Exit is on track for completion in Q4 2025, contributing to a 30.9% decrease in Other Markets sales year-to-date.

Sentiment

Score: 7

Explanation: The company demonstrated strong revenue and gross profit growth, driven by strategic acquisitions and demand. Significant debt restructuring improved the interest rate profile and liquidity. While year-to-date net income and EPS were negatively impacted by a large, one-time debt conversion expense, the underlying operational performance and Q3 EPS growth suggest a positive trajectory. The completion of the Portable Medical Exit is also a positive step towards portfolio optimization.

Positives

• Strong sales growth: Q3 2025 sales increased 8.4% to $467.691 million, and YTD 2025 sales increased 9.0% to $1,381.577 million.
• Gross profit improvement: Q3 2025 gross profit increased 8.2% to $126.160 million, and YTD 2025 gross profit increased 9.8% to $375.630 million, driven by higher sales volume and supply chain efficiencies.
• Strategic acquisitions: Precision Coating LLC and VSi Parylene acquisitions enhance service offerings and contributed $42.1 million to YTD Cardio & Vascular sales.
• Reduced interest expense: Q3 2025 interest expense decreased 35.7% to $9.367 million, and YTD 2025 decreased 21.4% to $33.926 million, primarily due to lower interest rates on outstanding borrowings.
• Improved debt structure: Floating-rate debt reduced to $101 million from $501 million, with 92% of principal debt now fixed rate, mitigating interest rate risk.
• Strong liquidity: Cash and cash equivalents increased to $58.944 million, and working capital from continuing operations increased by $124.4 million to $568.301 million.
• Compliance with covenants: Maintained Total Net Leverage Ratio of approximately 2.6:1.0 and interest coverage ratio of approximately 11.2:1.0, well within covenant limits.

Negatives

• Significant year-to-date net income and EPS decline: YTD 2025 net income decreased 37.8% to $54.200 million, and diluted EPS decreased 38.2% to $1.52, primarily due to a $46.7 million debt conversion inducement expense.
• Increased operating expenses: Q3 2025 operating expenses increased 19.1% to $69.721 million, and YTD 2025 increased 10.1% to $210.301 million, mainly due to higher SG&A and restructuring charges.
• Decline in Other Markets sales: Q3 2025 sales decreased 15.5% and YTD 2025 sales decreased 30.9% in Other Markets, primarily due to the Portable Medical Exit.
• Increased restructuring and other charges: YTD 2025 charges increased 56.5% to $16.377 million, including $6.2 million for termination benefits.
• Higher effective tax rate year-to-date: YTD 2025 effective tax rate was 31.0% compared to 18.7% in YTD 2024, largely due to the non-deductible induced conversion expense.

Risks

• Dependence on a limited number of customers and pricing pressures.
• Reliance on third-party suppliers for raw materials, key products, and subcomponents.
• Potential interruptions in manufacturing operations.
• Uncertainty surrounding macroeconomic and geopolitical factors, including supply chain disruptions, inflationary pressure, elevated interest rates, and conflicts in Russia-Ukraine and the Middle East.
• Ability to attract, train, and retain qualified associates.
• Potential for harm to reputation and competitive advantage from quality problems.
• Dependence on information technology systems and vulnerability to cyber-attacks.
• Impact of global climate change and ESG matters.
• Dependence on senior management and key technical personnel.
• Consolidation in the healthcare industry leading to greater competition.
• Ability to accurately forecast future performance due to fluctuating operating results.
• Significant outstanding indebtedness and ability to comply with financial and other covenants.
• Economic and credit market uncertainties that could interrupt access to capital markets.
• Conditional conversion feature of the 2028 and 2030 Convertible Notes potentially impacting liquidity.
• Dilution of ownership interests for existing common stock holders from the conversion of 2028 Convertible Notes.
• Counterparty risk associated with capped call transactions.
• Financial and market risks related to international sales and operations.
• Complex international tax profile and ability to realize full value of intangible assets.
• Regulatory issues from product complaints, recalls, or audits.
• Potential for product liability or intellectual property claims.
• Ability to protect intellectual property and proprietary rights.
• Compliance with customer-driven policies and third-party certification requirements.
• Ability to obtain and/or retain necessary licenses for new technologies.
• Costs and ability to comply with environmental regulations.
• Legal and regulatory risks from international operations.
• Healthcare industry cost containment measures potentially reducing product sales.

Future Outlook

The company expects to complete its Portable Medical Exit in the fourth quarter of 2025. Management believes that projected cash flows from operations, available cash, and revolving credit facility borrowings are sufficient to meet working capital, debt service, and capital expenditure requirements for the next twelve months. The company continues to evaluate the potential impact of the EU's Pillar Two Directive and the OBBBA tax reform, but does not anticipate a material impact from OBBBA to the condensed consolidated financial statements.

Management Comments

• Committed to enhancing the lives of patients worldwide by providing innovative, high-quality products and solutions.
• The acquisitions of Precision and VSi further increase our service offerings to include differentiated and proprietary coatings capabilities that position us to better meet customers evolving needs.
• The Portable Medical Exit will be completed with the final sales and market exit occurring during the fourth quarter of 2025.
• Based on current expectations, we believe that our projected cash flows provided by operations, available cash and cash equivalents and borrowings under our Revolving Credit Facility are sufficient to meet our working capital, debt service and capital expenditure requirements for the next twelve months.

Industry Context

The company operates in the highly regulated medical device contract development and manufacturing sector, serving cardiac rhythm management, neuromodulation, and cardio and vascular markets. Its strategic acquisitions of Precision Coating LLC and VSi Parylene reflect a trend towards expanding specialized service offerings, particularly in high-value surface coating and parylene solutions, to meet evolving customer needs in complex medical device applications. The ongoing Portable Medical Exit indicates a strategic focus on core, higher-growth medical markets. The industry faces macroeconomic and geopolitical uncertainties, including supply chain disruptions, inflation, and elevated interest rates, which the company is actively monitoring and managing.

Comparison to Industry Standards

• No specific comparable companies, projects, or global benchmarks were mentioned in the filing to assess the results against industry standards.

Legal Proceedings

• No new material legal proceedings were reported for the quarter ended September 26, 2025, and no material developments occurred in previously disclosed legal proceedings.

Stakeholder Impact

• Shareholders: Potential dilution from convertible notes conversion, impact on share price from financial results and strategic moves.
• Employees: Termination benefits related to labor alignment actions, integration of employees from acquired businesses.
• Customers: Expanded service offerings and capabilities through acquisitions (Precision, VSi), transition support for customers impacted by the Portable Medical Exit.
• Creditors: Significant changes in debt structure, including issuance of new convertible notes and repayment of existing facilities, impacting debt maturity profiles and interest rate exposure.
• Suppliers: Continued reliance on third-party suppliers for raw materials and components.

Next Steps

• Complete the Portable Medical Exit with final sales and market exit during the fourth quarter of 2025.
• Continue evaluating the impact of the EU's Pillar Two Framework on future periods.
• Monitor macroeconomic and geopolitical factors and take actions to align cost structure with demand and manage working capital.
• Continue to explore tax planning opportunities.
• Complete valuations for acquired assets and liabilities for Precision and VSi acquisitions.

Key Dates

Recommendation

The company shows strong underlying operational performance with robust sales and gross profit growth, supported by strategic acquisitions. The significant year-to-date earnings per share decline is primarily attributable to a one-time, non-recurring debt conversion inducement expense, which distorts the overall picture. The successful debt restructuring has improved the company's financial flexibility and reduced interest rate risk. However, the ongoing macroeconomic uncertainties, integration risks from recent acquisitions, and the impact of the Portable Medical Exit on "Other Markets" sales warrant a cautious approach. While the long-term strategic direction appears sound, a "hold" recommendation allows investors to observe the full integration of acquisitions and the complete exit from the portable medical market, as well as the sustained impact of the improved debt structure on future profitability, before making a more aggressive move.

Keywords

Medical Device, Contract Manufacturing, Cardiac Rhythm Management, Neuromodulation, Cardio & Vascular, SEC Filing, 10-Q, Financial Results, Acquisitions, Convertible Notes, Debt Restructuring, Parylene Coating, Surface Coating, Healthcare Industry, Supply Chain, Earnings, Revenue, EPS, ITGR